Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Abstract The tumor suppressor gene PTEN is the second most commonly deleted gene in cancer. Such deletions often include portions of the chromosome 10q23...

The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of...

Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate...

In this educational initiative, Stefano Fanti and Ken Herrmann join together to share their knowledge of PSMA PET and PSMA theranostics focusing on the...

Eric Small presents a discussion on primary small cell prostate cancer and therapeutic approaches to consider in aggressive variant prostate cancer (AVPC) and small...

A new approach that selectively seeks out and destroys prostate cancer cells represents a major leap forward for treating men with the...

Cora Sternberg joins Alicia Morgans in a discussion on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) highlighting the ARASENS trial. The treatment...

Abstract. Advanced prostate cancers comprise distinct phenotypes, but tumor classification remains clinically challenging. Here, we harnessed circulating tumor DNA (ctDNA) to study tumor phenotypes...

SUO 2022 advances in the field of bipolar androgen therapy in advanced prostate cancer, castration-resistant prostate cancer cell growth, human prostate cancer LNCaP cell...

At the 2022 Advanced Prostate Cancer Consensus Conference, Darren Poon presents the management of clinical N1 prostate cancer (including systemic therapy). Biographies: Darren Poon,...